Author:
Sun Binjie,Liu Zhen,Yin Hongshan,Wang Tao,Chen Tao,Yang Sen,Jiang Zhian
Publisher
Ovid Technologies (Wolters Kluwer Health)
Reference33 articles.
1. No-reflow is an independent predictor of death and myocardial infarction after percutaneous coronary intervention;Resnic;Am Heart J,2003
2. In-lab upfront use of tirofiban may reduce the occurrence of no-reflow during primary percutaneous coronary intervention. A pilot randomized study;Lago;Arq Bras Cardiol,2016
3. Appropriate bolus administration of glycoprotein IIb/IIIa inhibitors for patients with acute coronary syndromes undergoing percutaneous coronary intervention: intracoronary or intravenous? A comprehensive and updated meta-analysis and systematic review;Ali-Hassan-Sayegh;Kardiol Pol,2016
4. Meta-analysis of randomized controlled trials comparing intracoronary and intravenous administration of glycoprotein IIb/IIIa inhibitors in patients with ST-elevation myocardial infarction;Wang;Am J Cardiol,2012
5. Meta-analysis of randomized controlled trials of intracoronary versus intravenous administration of glycoprotein IIb/IIIa inhibitors during percutaneous coronary intervention for acute coronary syndrome;Friedland;Am J Cardiol,2011
Cited by
14 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献